Donald Trump’s decision to impose a 15 per cent tariff on medical devices imported from the EU will lead to higher prices for US patients and make the supply chain more vulnerable, senior industry figures claim.
Pharmaceutical and healthcare products have traditionally been spared from tariffs for ethical reasons, but there was no exemption for the EU’s multibillion-euro health tech industry when the EU and US announced its trade pact in July.
“We said at the time that this issue is ‘monumentally serious’ and we meant it. It’s a global industry and US patients will be affected,” said Oliver Bisazza, the chief executive of MedTech Europe, a lobby group.
您已閱讀11%（658字），剩余89%（5470字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。